PARP1 and neoplasm: We hypothesized that a dose-escalation strategy that incorporates tumor targeted DNA-damaging chemotherapy delivery alongside dose scheduling of PARP inhibitors could facilitate administration of effective PARP inhibitor-chemotherapy combinations24,25.